BRPI0920622A8 - vacina contra o vírus da doença equina africana - Google Patents

vacina contra o vírus da doença equina africana Download PDF

Info

Publication number
BRPI0920622A8
BRPI0920622A8 BRPI0920622A BRPI0920622A BRPI0920622A8 BR PI0920622 A8 BRPI0920622 A8 BR PI0920622A8 BR PI0920622 A BRPI0920622 A BR PI0920622A BR PI0920622 A BRPI0920622 A BR PI0920622A BR PI0920622 A8 BRPI0920622 A8 BR PI0920622A8
Authority
BR
Brazil
Prior art keywords
disease virus
equine disease
african equine
virus vaccine
african
Prior art date
Application number
BRPI0920622A
Other languages
English (en)
Inventor
John Guthrie Alan
Maarten Minke Jules
Audonnet Jean-Christophe
Yao Jiansheng
James Maclachlan Nigel
Original Assignee
Merial Ltd
Merial Inc
Univ California
Univ Pretoria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41818403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0920622(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merial Ltd, Merial Inc, Univ California, Univ Pretoria filed Critical Merial Ltd
Priority to BR122019001455-8A priority Critical patent/BR122019001455B1/pt
Publication of BRPI0920622A2 publication Critical patent/BRPI0920622A2/pt
Publication of BRPI0920622A8 publication Critical patent/BRPI0920622A8/pt
Publication of BRPI0920622B1 publication Critical patent/BRPI0920622B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

vacina contra o vírus da doença equina africana a presente invenção fornece vetores que contêm e expressam in vivo os genes que codificam vp2 e vps do vírus da doença equina africana ou um epítopo dos mesmos, que elicia · uma resposta imune em um cavalo contra o vírus da doença equina africana, composições compreendendo os ditos vetores, métodos de vacinação contra o vírus da doença equina africana, e kits para uso com tais métodos e composições.
BRPI0920622-1A 2008-10-24 2009-10-22 vacina contra o vírus da doença equina africana BRPI0920622B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019001455-8A BR122019001455B1 (pt) 2008-10-24 2009-10-22 vacina contra o vírus da doença equina africana

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10807508P 2008-10-24 2008-10-24
US16351709P 2009-03-26 2009-03-26
PCT/US2009/061669 WO2010048394A2 (en) 2008-10-24 2009-10-22 Vaccine against african horse sickness virus

Publications (3)

Publication Number Publication Date
BRPI0920622A2 BRPI0920622A2 (pt) 2016-10-04
BRPI0920622A8 true BRPI0920622A8 (pt) 2019-02-05
BRPI0920622B1 BRPI0920622B1 (pt) 2019-11-12

Family

ID=41818403

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122019001455-8A BR122019001455B1 (pt) 2008-10-24 2009-10-22 vacina contra o vírus da doença equina africana
BRPI0920622-1A BRPI0920622B1 (pt) 2008-10-24 2009-10-22 vacina contra o vírus da doença equina africana

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122019001455-8A BR122019001455B1 (pt) 2008-10-24 2009-10-22 vacina contra o vírus da doença equina africana

Country Status (19)

Country Link
US (3) US8168200B2 (pt)
EP (1) EP2358742B1 (pt)
JP (1) JP2012506699A (pt)
KR (1) KR101719005B1 (pt)
CN (1) CN102245627A (pt)
AP (1) AP3334A (pt)
AR (1) AR074055A1 (pt)
AU (1) AU2009308331C1 (pt)
BR (2) BR122019001455B1 (pt)
CA (1) CA2741333C (pt)
CL (1) CL2011000922A1 (pt)
EA (1) EA024111B1 (pt)
ES (1) ES2681693T3 (pt)
MX (1) MX2011004219A (pt)
NZ (2) NZ598605A (pt)
PL (1) PL2358742T3 (pt)
PT (1) PT2358742T (pt)
WO (1) WO2010048394A2 (pt)
ZA (1) ZA201103031B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101719005B1 (ko) * 2008-10-24 2017-03-22 메리얼 인코포레이티드 아프리카 마역 바이러스에 대한 백신
EP3466443B1 (en) 2012-02-14 2020-12-16 Boehringer Ingelheim Animal Health USA Inc. Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom
WO2016071850A1 (en) * 2014-11-04 2016-05-12 Deltamune (Pty) Limited Live attenuated african horsesickness virus
US11233998B2 (en) 2015-05-29 2022-01-25 Qualcomm Incorporated Coding data using an enhanced context-adaptive binary arithmetic coding (CABAC) design
EA202092165A1 (ru) * 2018-03-19 2021-02-25 Бёрингер Ингельхайм Ветмедика Гмбх Новый ehv сайт инсерции ul43
US12581092B2 (en) 2022-03-03 2026-03-17 Qualcomm Incorporated Temporal initialization points for context-based arithmetic coding
CN116041447A (zh) * 2022-12-29 2023-05-02 北京亿森宝生物科技有限公司 一种检测非洲马瘟病毒的试剂盒及其应用
CN116656731B (zh) * 2023-05-25 2024-04-12 军事科学院军事医学研究院军事兽医研究所 一种表达非洲猪瘟病毒多种蛋白的重组金丝雀痘病毒及其构建方法
EP4520797A1 (en) 2023-07-07 2025-03-12 Chukyo Yushi Co., Ltd. Dispersion
CN117737310B (zh) * 2024-01-26 2024-07-16 中国农业科学院北京畜牧兽医研究所 非洲马瘟和西尼罗病毒的双重实时荧光mira检测引物探针组、试剂盒及方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
DE69233158T2 (de) * 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
ZA976424B (en) * 1996-07-05 1999-01-22 Agricultural Research Council Nucleic acid sequences coding for african horsesickness virus outer capsid components
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) * 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
US7862821B2 (en) * 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
KR101719005B1 (ko) * 2008-10-24 2017-03-22 메리얼 인코포레이티드 아프리카 마역 바이러스에 대한 백신

Also Published As

Publication number Publication date
AU2009308331B2 (en) 2014-08-21
EA024111B1 (ru) 2016-08-31
MX2011004219A (es) 2011-09-22
WO2010048394A3 (en) 2010-08-19
KR101719005B1 (ko) 2017-03-22
NZ598605A (en) 2014-04-30
EP2358742A2 (en) 2011-08-24
EA201100674A1 (ru) 2011-12-30
JP2012506699A (ja) 2012-03-22
AR074055A1 (es) 2010-12-22
NZ592388A (en) 2012-03-30
AP3334A (en) 2015-07-31
US20100119546A1 (en) 2010-05-13
ES2681693T3 (es) 2018-09-14
CA2741333A1 (en) 2010-04-29
BR122019001455B1 (pt) 2021-01-19
CN102245627A (zh) 2011-11-16
BRPI0920622A2 (pt) 2016-10-04
US20140120133A1 (en) 2014-05-01
US20120114691A1 (en) 2012-05-10
AU2009308331A1 (en) 2010-04-29
KR20110092281A (ko) 2011-08-17
WO2010048394A2 (en) 2010-04-29
EP2358742B1 (en) 2018-02-28
PL2358742T3 (pl) 2018-08-31
BRPI0920622B1 (pt) 2019-11-12
CL2011000922A1 (es) 2011-09-16
CA2741333C (en) 2018-02-13
PT2358742T (pt) 2018-06-04
AP2011005954A0 (en) 2011-10-31
US8168200B2 (en) 2012-05-01
ZA201103031B (en) 2014-03-26
AU2009308331C1 (en) 2015-07-09

Similar Documents

Publication Publication Date Title
BRPI0920622A8 (pt) vacina contra o vírus da doença equina africana
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
MX2019008303A (es) Ácido ribonucleico modificado con nucleósidos para inducir una respuesta inmune contra el virus zika.
BR112016028755A2 (pt) anticorpo ou fragmento de ligação ao antígeno macromolécula, molécula de ácido nucleico, composição farmacêutica, antígeno, e, métodos para fabricar um anticorpo e para selecionar um anticorpo.
AR105470A1 (es) Métodos para inducir una respuesta inmune
AR080313A1 (es) Composiciones de virus de moquillo canino (cdv) recombinante y sus usos
BRPI1007721B1 (pt) composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
BRPI0510430A (pt) composições e métodos para vacinação mucosal
BR112018012694A2 (pt) composição de célula dendrítica, vacina de célula dendrítica, composição e kit
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
BR112012014624A8 (pt) suspensão homogênea de compostos de imunopotenciação e usos dos destes
DK1881845T3 (da) Nipah-virusvacciner
BR112021021542A2 (pt) Terapia celular alogênica de malignidades de células b com o uso de células t geneticamente modificadas que têm como alvo cd19
BR112014023414A2 (pt) vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos
BR112017028212A2 (pt) vacinação concomitante contra dengue e febre amarela
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
PH12017500216B1 (en) Vaccine in serotype-9 fowl adenovirus recombinant vector
BR112018008840A8 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
BR112014020025A8 (pt) Vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
CY1125328T1 (el) Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων
BR112018074910A2 (pt) composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
CO6362049A2 (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo
AR106501A1 (es) Adyuvante y composición de vacuna que lo contiene

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MERIAL, INC. (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) ; UNIVERSITY OF PRETORIA (ZA) ; BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)